Companies › Everest Medicines (China)
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology, Genitourinary; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EVER001 Acts on multiple immune pathways without directly affecting T cells or depleting B cells | – | Phase 2 | Minimal Change Disease (MCD) | Dec 2028 |
| EVM14 Cancer vaccine | – | Phase 1 | Selected Types of Solid Tumor | Nov 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07614477 | EVER001 | Phase 2 | Minimal Change Disease (MCD) | Genitourinary | Dec 2028 |
| NCT07095868 | EVM14 | Phase 1 | Selected Types of Solid Tumor | Oncology | Nov 2029 |
No annotated target.
–
Calico Life Sciences Alentis Therapeutics Shenzhen Kangzhe Biotechnology iTeos Therapeutics LG Chem
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.